InterCure

INCRPre-clinical

intercure.co.il

InterCure is a vertically integrated medical cannabis company that develops, produces, and distributes pharmaceutical-grade cannabis products under its 'Canndoc' brand. The company is focused on clinical research, GMP compliance, and expanding its international footprint through strategic partnerships and acquisitions. As a public company on the NASDAQ and TASE, InterCure aims to establish itself as a global leader in the medical cannabis sector by providing standardized, research-backed treatments.

Market Cap

$42.3M

Employees

100-250

Focus

Biotech

AI Company Overview

Technology Platform

Vertically integrated platform for pharmaceutical-grade medical cannabis, encompassing proprietary cultivation, GMP manufacturing, and clinical research to develop standardized cannabis-based treatments.

Opportunities

Significant growth opportunity lies in the expansion into regulated European medical cannabis markets, where demand is rising and GMP-certified suppliers are favored.

Further opportunity exists in developing advanced, proprietary formulations and securing reimbursement status for specific indications, moving up the value chain.

Risk Factors

Key risks include stringent and evolving global cannabis regulations, intense competition from larger and better-capitalized rivals, pricing pressures, and the inherent operational risks of agricultural production.

Financial market volatility specific to cannabis stocks also poses a risk to capital raising.

Competitive Landscape

Competes with large Canadian Licensed Producers (Canopy, Tilray, Aurora) and local producers in Israel and Europe. Differentiation is based on pharmaceutical-grade GMP standards, vertical integration for quality control, a strong foundation in the research-oriented Israeli market, and a focus on medical channels rather than adult-use.